- Home
- OIA vs CCCC Comparison
OIA vs CCCC Comparison
Compare OIA & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIA | CCCC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.7M | 185.1M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OIA | CCCC |
|---|---|---|
| Price | $6.01 | $2.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 78.4K | ★ 2.6M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $5.43 | $1.09 |
| 52 Week High | $6.40 | $3.82 |
Technical Indicators
Market Signals| Indicator | OIA | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 44.03 |
| Support Level | $5.93 | $2.31 |
| Resistance Level | $6.11 | $2.52 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 53.12 | 0.00 |
Price Performance
Historical ComparisonAbout OIA Invesco Municipal Income Opportunities Trust
Invesco Muni Income Opps Trust operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income which is exempt from federal income tax.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.